What is Curiox Biosystems?
Curiox Biosystems is a specialized bioinstrumentation firm that emerged from the Agency for Science, Technology, and Research (A*STAR) in Singapore. The company focuses on the development and commercialization of advanced assay platforms, leveraging deep expertise in surface chemistry and precision engineering. By prioritizing the miniaturization and automation of bioassays, Curiox addresses significant bottlenecks in life sciences research, drug discovery, and clinical diagnostics. Its market position is defined by its ability to provide high-throughput, reproducible results that are essential for modern pharmaceutical development and laboratory efficiency.
How much funding has Curiox Biosystems raised?
Curiox Biosystems has raised a total of $33.2M across 3 funding rounds:
Series A
$3.2M
Series B
$15M
Series C
$15M
Series A (2010): $3.2M with participation from Zicom Group
Series B (2019): $15M led by SV Investment, HB Investment, DAYLI Investment, QUAD Investment, IMM Investment, and KB Investment
Series C (2022): $15M supported by Quad Investment Management, KB Investment, and Luha Private Equity
Key Investors in Curiox Biosystems
Quad Investment Management
A specialized investment firm focused on identifying high-growth opportunities within the technology and healthcare sectors.
KB Investment
KB Investment is a venture capital and private equity firm. It offers investment in venture companies that offer innovative technology, service, and entrepreneurship. The company was established in 1990 and is headquartered in Seoul, South Korea.
Zicom Group
An industrial and engineering-focused investment entity that provides strategic backing to companies developing complex technical solutions.
What's next for Curiox Biosystems?
With the recent infusion of capital, Curiox Biosystems is well-positioned to accelerate its global commercialization strategy. The company is expected to focus on deepening its penetration into the drug discovery market by enhancing its automated platform offerings. Strategic priorities likely include the expansion of its technical support infrastructure and the pursuit of new partnerships within the biopharmaceutical sector to integrate its assay technology into broader research workflows. As the firm moves beyond its current growth phase, the focus will shift toward sustaining its competitive advantage in surface chemistry while scaling its manufacturing capabilities to meet the rising demand for high-precision diagnostic tools.
See full Curiox Biosystems company page
